Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 2015; 14: 130-46.
Heptinstall AB, Adiyasa IWS, Cano C, Hardcastle IR. Recent advances in CDK inhibitors for cancer therapy. Future Med Chem 2018; 10: 1369-88.
Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod 2016; 79: 629-61.
Bharate SB, Sawant SD, Singh PP, Vishwakarma RA. Kinase inhibitors of marine origin. Chem Rev 2013; 113: 6761-815.
Singh U, Chashoo G, Khan SU, et al. Design of novel 3-Pyrimidinylazaindole CDK2/9 inhibitors with potent in vitro and in vivo antitumor efficacy in a triple-negative breast cancer model. J Med Chem 2017; 60: 9470-89.
Meerloo VJ, Kaspers GJL, Cloos J. Cell Sensitivity assays: The
MTT assay In: Cree I, Ed. Cancer Cell Culture Methods in Molecular
Biology (Methods and Protocols). 2000; p. 731.
Pozarowski P, Darzynkiewicz Z. Analysis of cell cycle by flow cytometry methods. Mol Biol 2004; 281: 301-11.
Chashoo G, Singh SK, Sharma PR, et al. A propionyloxy derivative of 11-keto-β-boswellic acid induces apoptosis in HL-60 cells mediated through topoisomerase I & II inhibition. Chem Biol Interact 2011; 189: 60-71.
Kumar A, Qayum A, Sharma PR, Singh SK, Shah BA. Synthesis of b-boswellic acid derivatives as cytotoxic and apoptotic agents. Bioorg Med Chem Lett 2016; 26: 76-81.
Majeed R, Hamid A, Sangwan PL, et al. Inhibition of phosphotidylinositol-3 kinase pathway by a novel naphthol derivative of betulinic acid induces cell cycle arrest and apoptosis in cancer cells of different origin. Cell Death Dis 2014; 5e1459
Pozzi S, Cirstea D, Santo L, et al. CYC065, A potent derivative of seliciclib is active in multiple myeloma in preclinical studies. Blood 2010; 116: 2999.
Ingrid AM, Arteaga CL. The Pi3k/Akt Pathway As A Target For Cancer Treatment ingrid A. Annu Rev Med 2016; 67: 11-28.
Foster KG, Fingar DC. Mammalian Target of Rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem 2010; 285: 14071-7.
Wang Q, Chen X, Hay N. Akt as a target for cancer therapy: More is not always better (lessons from studies in mice). Br J Cancer 2017; 17: 159-63.
Liang J, Zubovitz J, Petrocelli T, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002; 8: 1153-60.
Maddika S, Panigrahi S, Wiechec E, Wesselborg S, Fischer U, Schulze-Osthoff K. Los Marek. Unscheduled Akt-triggered activation of cyclin-dependent kinase 2 as a key effector mechanism of apoptin’s anticancer toxicity. Mol Cell Biol 2009; 29: 1235-48.
Saxton RA, Sabatini DM. mtor signaling in growth, metabolism, and disease. Cell 2017; 169: 361-71.
Ilagan E, Manning DB. Emerging role of mTOR in the response to cancer therapeutics. Trends Cancer 2016; 2: 241-51.